Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Acta Orthop Belg ; 83(1): 180-193, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29322911

RESUMEN

This study aimed to systematically compare the safety, effectiveness and radiological changes after lumbar pedicular dynamic stabilisation systems and fusion to treat lumbar degenerative disc disease . All studies that were performed to compare various lumbar pedicular dynamic stabilisation systems with any lumbar fusion to treat lumbar degenerative disc disease and were published until April 30, 2015 were acquired through a comprehensive search in various databases. A meta-analysis was performed after the methodological qualities of trials were assessed and after data were extracted. Sixteen trials with 881 patients with a short-term follow-up (within 2 years) and a middle-term follow-up (2 to 4 years) were identified. Patients treated with lumbar pedicular dynamic stabilisation systems experienced more significant advantages in terms of operation time, intra-operative blood loss, complications and adjacent segment degeneration/disease development than those treated with lumbar fusion. The two groups did not significantly differ in terms of improvement in Oswestry Disability Index, visual analogue scale scores, satisfaction rate of operation and range of motion of adjacent segments. Lumbar pedicular dynamic stabilisation systems is superior to lumbar fusion to some extent, although some of its advantages have yet to be verified and compared with those of lumbar fusion. However, the two interventions were not significantly different in terms of relief in symptoms, functional recovery and motion preservation. Thus, lumbar pedicular dynamic stabilisation systems is recommended for its safety. A prudent attitude is necessary to choose between these interventions on the basis of effectiveness and changes in adjacent segments before a large-scale and long-term follow-up study can be performed.


Asunto(s)
Fijadores Internos , Degeneración del Disco Intervertebral/cirugía , Vértebras Lumbares/cirugía , Rango del Movimiento Articular , Fusión Vertebral/instrumentación , Pérdida de Sangre Quirúrgica , Humanos , Fijadores Internos/efectos adversos , Degeneración del Disco Intervertebral/complicaciones , Degeneración del Disco Intervertebral/diagnóstico por imagen , Tiempo de Internación , Dolor de la Región Lumbar/etiología , Vértebras Lumbares/diagnóstico por imagen , Tempo Operativo , Satisfacción del Paciente , Complicaciones Posoperatorias/etiología , Radiografía , Fusión Vertebral/efectos adversos , Articulación Cigapofisaria/fisiopatología
2.
Scand J Rheumatol ; 42(4): 270-5, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23463945

RESUMEN

OBJECTIVES: Published studies have shown conflicting results concerning the association between the -169T/C promoter polymorphism in the Fc receptor-like 3 (FCRL3) gene and rheumatoid arthritis (RA). In this study we conducted an up-to-date meta-analysis to examine the relationship. METHOD: We searched the PubMed database for all papers published up to 20 April 2012. Overall, 18 case-control studies with 12 620 cases and 12 613 controls were retrieved based on the search criteria for RA susceptibility related to the FCRL3 -169T/C polymorphism. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of this association. Publication bias was assessed using the Egger test. RESULTS: We found that the FCRL3 -169T/C polymorphism increased the risk for RA overall in genetic models (allelic contrast: OR 1.09, 95% CI 1.03-1.14, p = 0.001; homozygote comparison: OR 1.20, 95% CI 1.08-1.34, p = 0.001; dominant genetic model: OR 1.03, 95% CI 1.01-1.05, p = 0.001). Stratified analysis by race also showed a significant positive association with Asians and Caucasians. Subgroup analysis of rheumatoid factor (RF) revealed a slightly positive relationship between the FCRL3 -169T/C polymorphism and RF-positive RA risk. No obvious evidence of publication bias was detected in the overall analysis. CONCLUSION: Our study indicates that the FCRL3 -169T/C polymorphism is significantly associated with increased RA risk.


Asunto(s)
Artritis Reumatoide/epidemiología , Artritis Reumatoide/genética , Predisposición Genética a la Enfermedad/epidemiología , Polimorfismo Genético , Receptores Inmunológicos/genética , Estudios de Casos y Controles , Intervalos de Confianza , Femenino , Regulación de la Expresión Génica , Humanos , Incidencia , Masculino , Oportunidad Relativa , Medición de Riesgo , Sensibilidad y Especificidad
3.
Eur Rev Med Pharmacol Sci ; 22(4): 1126-1132, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29509266

RESUMEN

OBJECTIVE: To investigate the effects of ulinastatin on inflammatory response and cognitive function after hip arthroplasty for the elderly patients with femoral neck fracture. PATIENTS AND METHODS: A total of 80 patients with femoral neck fracture receiving hip arthroplasty in our hospital from August 2016 to February 2017 were selected and divided into observation group (n=40) and control group (n=40) using a random number table. The control group was treated with hip arthroplasty and symptomatic and supportive treatment after operation, while the observation group was treated with ulinastatin based on the treatment means of control group. The changes in antioxidant capacities, plasma noradrenaline (NA) and adrenaline (A) levels between the two groups before and after intervention were compared. The changes in neuron-specific enolase (NSE) and plasma S-100B protein levels before intervention and at 48 h after intervention were also compared. Moreover, the changes in mini-mental state examination (MMSE) scores during intervention and the Harris hip scores before intervention and at discharge between the two groups were compared. Finally, the off-bed walking time and postoperative discharge time of the two groups were recorded. RESULTS: After intervention, the levels of malondialdehyde (MDA) and superoxide dismutase (SOD) and the total antioxidant capacity in observation group were significantly superior to those in observation group before intervention and control group after intervention (p<0.05). After intervention, the levels of NA and A in observation group were lower than those in control group (p<0.05), and the levels of interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) in observation group were also lower than those in control group (p<0.05). At 48 h after intervention, the levels of NSE and plasma S-100B protein in observation group were significantly lower than those in observation group before intervention and control group at 48 h after intervention (p<0.05). At 12 h, 24 h and 48 h after intervention, the MMSE scores of observation group were superior to those of control group in the same period (p<0.05). After intervention, the Harris hip score of observation group was superior to that of control group before and after intervention (p<0.05). The postoperative discharge time of observation group was earlier than that of control group (p<0.05), and the off-bed walking time was also earlier than that of control group (p<0.05). CONCLUSIONS: The combined application of ulinastatin could effectively reduce the oxidative stress and inflammatory response, improve the neurological functions, and promote the postoperative recovery in the elderly patients with femoral neck fracture after hip arthroplasty.


Asunto(s)
Artroplastia de Reemplazo de Cadera/psicología , Cognición/efectos de los fármacos , Fracturas del Cuello Femoral/tratamiento farmacológico , Glicoproteínas/uso terapéutico , Mediadores de Inflamación/sangre , Estrés Oxidativo/efectos de los fármacos , Adulto , Anciano , Artroplastia de Reemplazo de Cadera/tendencias , Cognición/fisiología , Femenino , Fracturas del Cuello Femoral/cirugía , Glicoproteínas/farmacología , Humanos , Mediadores de Inflamación/antagonistas & inhibidores , Masculino , Persona de Mediana Edad , Estrés Oxidativo/fisiología , Alta del Paciente/tendencias , Resultado del Tratamiento , Inhibidores de Tripsina/farmacología , Inhibidores de Tripsina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA